Mestag Therapeutics Ltd. has raised a $40 million round from existing investors as it completes final preparations for its lead program MST-0312 to enter clinical development in mid-2026. MST-0312 is a bispecific antibody aimed at the lymphotoxin-β receptor (LTBR), which is essential for the development of lymphoid tissues. Read More
Enodia Therapeutics Inc. was spun out of The Institut Pasteur by Argobio Studio based on the work of Caroline Demangel, co-founder of Enodia and head of the immunobiology and therapy unit at The Institut Pasteur. Demangel’s lab discovered the mechanism of action of mycolactone, a natural Sec61 inhibitor that causes Buruli ulcers. Read More
Ascletis Pharma Inc. has selected ASC-39, an amylin-selective oral small-molecule amylin receptor agonist, as a clinical development candidate. Read More
Sprint Bioscience AB has announced positive results from a preclinical proof-of-concept (POC) study performed within the company’s VRK1 program that showed that VRK1 inhibition selectively kills glioblastoma cells with low VRK2 levels, while cells with normal VRK2 levels are not affected. Read More
Gasherbrum Bio Inc. has discovered new glucagon-like peptide 1 receptor (GLP-1R) agonists. They are reported to be useful for the treatment of type 2 diabetes, dyslipidemia, hyperglycemia, hypertension, obesity and more. Read More
Acumen Pharmaceuticals Inc. has announced a $35.75 million private placement to advance molecules from its amyloid-β oligomer-selective Enhanced Brain Delivery (EBD) portfolio for the treatment of Alzheimer’s disease. Read More
Facioscapulohumeral muscular dystrophy (FSHD) is a muscle wasting disease caused by aberrant expression of double homeobox protein 4 (DUX4). When DUX4 is activated in skeletal muscle, it triggers myocyte cell death after several transcriptional changes, thus genetic DUX4 silencing arises as a promising approach for treating FHSD. Read More
Boomray Co. Ltd. has prepared and tested new peptide-drug conjugates comprising a radionuclide-labeled probe linked to a fibroblast activation protein α (FAP)-targeting peptide. They are reported to be useful for the diagnosis and treatment of cancer, inflammation, atherosclerosis, fibrosis and scars. Read More
Breye Therapeutics Aps has reported P2X purinoceptor 7 (P2RX7; P2X7) antagonists potentially useful for the treatment of age-related macular degeneration (AMD), cardiovascular, cognitive, eating disorder, headache, liver diseases, neurodegeneration and neuroinflammation, among others. Read More
A recent study aimed to de novo design mini-protein inhibitors that specifically block the membrane insertion of soluble complement C9. This work, led by researchers from Shandong Second Medical University, applied deep learning-based methods for protein scaffold generation, sequence design and complex structure prediction. Read More
A University of Texas System patent describes new YAP1 degradation inducing proteolysis targeting chimeras (PROTACs) designed for use in the treatment of cancer. Read More
Asieris Pharmaceuticals Co. Ltd. has patented new prodrugs of fibroblast growth factor receptor 3 (FGFR3) inhibitors potentially useful for the treatment of cancer. Read More
Alloy Therapeutics Inc. has entered into an agreement with Abbvie Inc. to develop a new antibody platform to discover antibodies against targets that are difficult to address with current technologies. Read More
